文献速递临床试验与 GCP新药、器械与细胞基因治疗研发流行病学与生物统计

早期临床试验在FDA批准靶向抗癌药物适应症中发挥关键作用:2012至2021年横断面研究

Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021.
PubMed 文献 · J Clin Epidemiol · 2023-03-10

该横断面研究收集2012年1月至2021年12月FDA批准的靶向抗癌药物公开文件,共识别95种药物、188项适应症,其中112项(59.6%)基于早期临床试验获批,每年显著增长22.2%。与基于三期随机对照试验的适应症相比,基于早期临床试验的适应症获得加速批准的优势比显著更高,关键试验入组患者数的优势比显著更低。

要点

  • 188项靶向抗癌药适应症中112项(59.6%)基于早期临床试验获批,每年显著增长22.2%。
  • 112项早期临床试验中32项(28.6%)为剂量扩展队列试验,75项(67.0%)为单臂2期试验。
  • 基于早期临床试验的适应症较基于三期随机对照试验者加速批准优势比显著更高、关键试验入组患者数优势比显著更低。

核心结论

  • 剂量扩展队列试验和单臂2期试验在早期临床试验中发挥关键作用,早期临床试验是FDA批准靶向抗癌药物适应症的主要试验类型。

研究设计与样本

  • 横断面研究,收集2012年1月至2021年12月美国FDA批准的靶向抗癌药物公开文件。
  • 共识别95种靶向抗癌药物、188项FDA批准的适应症。

主要发现

  • 112项(59.6%)适应症基于早期临床试验获批,每年显著增长22.2%。
  • 112项早期临床试验中,32项(28.6%)为剂量扩展队列试验,75项(67.0%)为单臂2期试验,分别每年显著增长29.7%和18.7%。
  • 与基于三期随机对照试验的适应症相比,基于早期临床试验的适应症获得加速批准的优势比显著更高。
  • 与基于三期随机对照试验的适应症相比,基于早期临床试验的适应症在关键试验入组患者数方面的优势比显著更低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the indications approved by the US Food and Drug Administration (FDA) on the basis of early phase clinical trials (EPCTs) and compared with that of phase three randomized controlled trials. STUDY DESIGN AND SETTING: We collected the publicly available FDA documents of targeted anticancer drugs approved between January 2012 and December 2021. RESULTS: We identified 95 targeted anticancer drugs with 188 indications approved by the FDA. One hundred and twelve (59.6%) indications were approved on the basis of EPCTs, with a significant increase of 22.2% per year. Of 112 EPCTs, 32 (28.6%) were dose-expansion cohort trials and 75 (67.0%) were single-arm phase 2 trials, respectively, with a significant increase of 29.7% and 18.7% per year. Compared with indications approved on the basis of phase three randomized controlled trials, the indications approved on the basis of EPCTs had significantly higher odds in receiving accelerated approval and lower odds in the number of entered patients of pivotal trials. CONCLUSIONS: Dose-expansion cohort trials and single-arm phase 2 trials played a critical role in EPCTs. EPCT was a major trial type in providing evidences for the FDA approvals of targeted anticancer drugs.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Huang Y, Xiong W, Zhao J, et al. Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021. J Clin Epidemiol. 2023. PMID: 36905971. doi:10.1016/j.jclinepi.2023.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。